[go: up one dir, main page]

CY1105943T1 - Συνθεση εμβολιου - Google Patents

Συνθεση εμβολιου

Info

Publication number
CY1105943T1
CY1105943T1 CY20071100081T CY071100081T CY1105943T1 CY 1105943 T1 CY1105943 T1 CY 1105943T1 CY 20071100081 T CY20071100081 T CY 20071100081T CY 071100081 T CY071100081 T CY 071100081T CY 1105943 T1 CY1105943 T1 CY 1105943T1
Authority
CY
Cyprus
Prior art keywords
vaccine composition
elicit
cationic lipid
immune response
type immune
Prior art date
Application number
CY20071100081T
Other languages
English (en)
Inventor
Jean Haensler
Christian Marcel Hurpin
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of CY1105943T1 publication Critical patent/CY1105943T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Η εφεύρεση αφορά μια σύνθεση εμβολίου η οποία περιέχει τουλάχιστον ένα ανοσοδιεγερτικό αντιγόνο, ένα κατιονικό λιπίδιο και ένα ολιγονουκλεοτίδιο. Η σύνθεση αυτή εμβολίου προορίζεται συγκεκριμένα για την πρόκληση μιας ανοσοαπόκρισης τύπου Th1 και μιας Τ κυτταροτοξικής απόκρισης κατά τη διάρκεια της χορήγησης της δια της παρεντερικής οδού, και για την πρόκληση μιας ανοσοαπόκρισης τύπου Th2 κατά τη διάρκεια της χορήγησης της δια της οδού του βλεννογόνου. Η σύνθεση αυτή εμβολίου έχει ένα συγκεκριμένο ενδιαφέρον όταν το κατιονικό λιπίδιο είναι η DC-χόλη.
CY20071100081T 2000-10-06 2007-01-23 Συνθεση εμβολιου CY1105943T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale
PCT/FR2001/003098 WO2002028428A2 (fr) 2000-10-06 2001-10-08 Composition vaccinale

Publications (1)

Publication Number Publication Date
CY1105943T1 true CY1105943T1 (el) 2011-04-06

Family

ID=8855083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100081T CY1105943T1 (el) 2000-10-06 2007-01-23 Συνθεση εμβολιου

Country Status (12)

Country Link
US (3) US20040038922A1 (el)
EP (2) EP1326635B1 (el)
AT (2) ATE350057T1 (el)
AU (2) AU2001295673A1 (el)
CA (1) CA2424836A1 (el)
CY (1) CY1105943T1 (el)
DE (2) DE60110822T2 (el)
DK (1) DK1326636T3 (el)
ES (2) ES2240526T3 (el)
FR (1) FR2814958B1 (el)
PT (2) PT1326635E (el)
WO (2) WO2002028427A2 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69932717T2 (de) * 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
NZ552377A (en) * 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
EP2484374A1 (en) * 2004-07-18 2012-08-08 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
CN105705164A (zh) 2013-10-04 2016-06-22 品诺制药公司 用于癌症治疗的免疫刺激性hiv tat衍生多肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
EP1574210B1 (en) * 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Microemulsions with adsorbed macromolecules
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
EP1326635A2 (fr) 2003-07-16
ATE295180T1 (de) 2005-05-15
EP1326636B1 (fr) 2007-01-03
FR2814958B1 (fr) 2003-03-07
EP1326635B1 (fr) 2005-05-11
US20030190326A1 (en) 2003-10-09
WO2002028427A2 (fr) 2002-04-11
WO2002028428A3 (fr) 2003-02-20
ATE350057T1 (de) 2007-01-15
DE60125797T2 (de) 2007-12-06
DE60125797D1 (de) 2007-02-15
CA2424836A1 (en) 2002-04-11
ES2240526T3 (es) 2005-10-16
PT1326635E (pt) 2005-08-31
ES2275738T3 (es) 2007-06-16
EP1326636A2 (fr) 2003-07-16
WO2002028428A2 (fr) 2002-04-11
DE60110822T2 (de) 2006-05-11
US20040038922A1 (en) 2004-02-26
DE60110822D1 (de) 2005-06-16
US20050118188A1 (en) 2005-06-02
DK1326636T3 (da) 2007-04-30
AU2001295671A1 (en) 2002-04-15
FR2814958A1 (fr) 2002-04-12
WO2002028427A3 (fr) 2003-03-20
PT1326636E (pt) 2007-02-28
AU2001295673A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
CY1105943T1 (el) Συνθεση εμβολιου
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CY1107457T1 (el) Εμβoλιο κατa του hpv
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
NO20015073D0 (no) Vaksiner
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
WO2001060402A3 (en) Proteosome influenza vaccine
Gerdts et al. Carrier molecules for use in veterinary vaccines
EP2281573A3 (en) Influenza vaccine formulations for intradermal delivery
BR0215089A (pt) Vacina de streptococcus pneumoniae melhorada, e, métodos de eliciação de uma resposta imune protetora em lactentes e em idosos contra s. pneumoniae, e, em lactentes contra otite média
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2001068129A3 (de) Adjuvans für vakzinen
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
DK1259259T3 (da) Mucosal adjuvansformulering
CY1108526T1 (el) Εμβολια εναντι καρκινων
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2001000231A3 (en) Use of cpg as an adjuvant for malaria vaccine
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide